Year: 2025
Type: article
Abstract: The pediatric drug discovery pipeline is a vital part of pharmaceutical research, focusing on developing and optimizing medications specifically for children. This process differs significantly from adult drug development due to age-related physiological differences, developmental changes, and the need for age-appropriate formulations. Key stages include preclinical studies, which assess drug mechanisms and safety in non-human models, and clinical trials that evaluate efficacy and safety in pediatric patients. Despite its importance, pediatric drug development faces substantial challenges, including limited clinical trial data, ethical concerns in testing on minors, and strict regulatory requirements for pediatric-specific studies. Studies indicate that only 50–60% of drugs used in pediatrics have been formally tested in children, underscoring a critical gap in evidence-based pharmacotherapy. The process is further complicated by the need for precise dosing across various age groups, requiring specialized formulations. Recent advancements aim to address these challenges. Over the past decade, pediatric clinical trials have increased by 20%, driven by regulatory incentives, technological innovations in drug delivery, and stronger collaborations between research institutions, industry, and regulators. The adoption of pediatric-specific trial designs and improved data-sharing mechanisms has further enhanced development efforts. From a policy and industry perspective, strengthening incentives, streamlining regulatory pathways, and fostering interdisciplinary research are essential to accelerating pediatric drug innovation. This review highlights the evolving landscape of pediatric drug development, emphasizing the need for continuous improvement to ensure that children receive safe, effective, and appropriately dosed medications.
Institutions: University of Karachi, Air University, Air University
Language: English
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W4410113334